1. Home
  2. ELVN vs DCBO Comparison

ELVN vs DCBO Comparison

Compare ELVN & DCBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • DCBO
  • Stock Information
  • Founded
  • ELVN 2016
  • DCBO 2016
  • Country
  • ELVN United States
  • DCBO Canada
  • Employees
  • ELVN N/A
  • DCBO N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • DCBO
  • Sector
  • ELVN Health Care
  • DCBO
  • Exchange
  • ELVN Nasdaq
  • DCBO Nasdaq
  • Market Cap
  • ELVN 927.8M
  • DCBO 795.1M
  • IPO Year
  • ELVN 2020
  • DCBO 2020
  • Fundamental
  • Price
  • ELVN $21.30
  • DCBO $26.19
  • Analyst Decision
  • ELVN Strong Buy
  • DCBO Buy
  • Analyst Count
  • ELVN 5
  • DCBO 6
  • Target Price
  • ELVN $39.60
  • DCBO $42.50
  • AVG Volume (30 Days)
  • ELVN 594.3K
  • DCBO 77.7K
  • Earning Date
  • ELVN 08-12-2025
  • DCBO 08-07-2025
  • Dividend Yield
  • ELVN N/A
  • DCBO N/A
  • EPS Growth
  • ELVN N/A
  • DCBO 268.72
  • EPS
  • ELVN N/A
  • DCBO 0.74
  • Revenue
  • ELVN N/A
  • DCBO $222,824,000.00
  • Revenue This Year
  • ELVN N/A
  • DCBO $13.57
  • Revenue Next Year
  • ELVN N/A
  • DCBO $13.40
  • P/E Ratio
  • ELVN N/A
  • DCBO $33.99
  • Revenue Growth
  • ELVN N/A
  • DCBO 16.79
  • 52 Week Low
  • ELVN $13.30
  • DCBO $25.50
  • 52 Week High
  • ELVN $30.03
  • DCBO $53.86
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 55.53
  • DCBO 40.65
  • Support Level
  • ELVN $18.53
  • DCBO $26.18
  • Resistance Level
  • ELVN $24.11
  • DCBO $27.39
  • Average True Range (ATR)
  • ELVN 1.96
  • DCBO 0.69
  • MACD
  • ELVN 0.15
  • DCBO 0.03
  • Stochastic Oscillator
  • ELVN 55.68
  • DCBO 2.90

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

Share on Social Networks: